Biogen Inc. Free Cash Flow 2007–2025
Biogen Inc. reported $2.05B of free cash flow for fiscal 2025. That was 24.7% lower than fiscal 2024. Compared with fiscal 2020, the change was -46.1%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $2.05B | -24.7% |
| FY 2024 | $2.72B | +114.3% |
| FY 2023 | $1.27B | +11.0% |
| FY 2022 | $1.14B | -66.2% |
| FY 2021 | $3.38B | -11.1% |
| FY 2020 | $3.81B | -42.0% |
| FY 2019 | $6.56B | +21.2% |
| FY 2018 | $5.42B | +47.1% |
| FY 2017 | $3.68B | -7.2% |
| FY 2016 | $3.97B | +21.2% |
| FY 2015 | $3.28B | +23.4% |
| FY 2014 | $2.65B | +26.5% |
| FY 2013 | $2.10B | +29.1% |
| FY 2012 | $1.63B | +7.0% |
| FY 2011 | $1.52B | +4.7% |
| FY 2010 | $1.45B | +59.6% |
| FY 2009 | $909.25M | -29.3% |
| FY 2008 | $1.29B | +75.1% |
| FY 2007 | $734.65M | — |
Source: Biogen Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open BIIB 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Biogen Inc. reported $2.05B of free cash flow for fiscal 2025. That was 24.7% lower than fiscal 2024. Compared with fiscal 2020, the change was -46.1%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Biogen Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeBiogen Inc. — frequently asked questions
What is Biogen Inc.'s free cash flow?
Biogen Inc. (BIIB) reported free cash flow of $2.05B for fiscal year 2025, per its SEC filings.
How has Biogen Inc.'s free cash flow changed over time?
Between fiscal 2007 and 2025, BIIB's free cash flow grew at roughly 5.9% per year (compound annual rate), from $734.65M to $2.05B.
Where does this data come from?
Figures are computed from Biogen Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.